Evidence-practice gaps in P2Y12 inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia.
Michael O FalsterAndrea L SchafferAndrew WilsonArthur NasisLouisa R JormMelanie HayKira LeebSallie-Anne PearsonDavid BriegerPublished in: Internal medicine journal (2020)
Post-hospitalisation use of P2Y12 inhibitor therapy in AMI patients is low, and varies substantially by hospital of discharge. Our findings suggest strategies addressing both health system (hospital and physician) and patient factors are needed to close this evidence-practice gap. This article is protected by copyright. All rights reserved.
Keyphrases
- acute myocardial infarction
- healthcare
- primary care
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- emergency department
- percutaneous coronary intervention
- prognostic factors
- case report
- peritoneal dialysis
- adverse drug
- left ventricular
- quality improvement
- acute care
- stem cells
- gene expression
- dna methylation
- deep learning
- atrial fibrillation
- coronary artery disease
- bone marrow
- human immunodeficiency virus
- cell therapy
- smoking cessation
- antiretroviral therapy
- hiv testing
- drug induced